Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on November 19, 2022. The registrant is incorporated in California and its principal executive offices are located in Irvine, California. The report discloses a specific corporate governance event regarding the Board of Directors.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting a personnel change and does not provide a clear value for any financial metric.
Material Changes
The primary material change reported is the resignation of Melinda Griffith from the Board of Directors, effective January 1, 2023. Ms. Griffith served as the Chair of the Nominating/Corporate Governance Committee and was a member of the Sciences and Technology Committee. The Company explicitly states that her resignation was not due to any disagreement with the Company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No new risks, contingencies, or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Verify the effective date of Melinda Griffith's resignation (January 1, 2023).
- Confirm the composition of the Board of Directors following this departure.
- Note that the resignation was voluntary and unrelated to any disagreement with company management.
- Check subsequent filings for any appointment of a replacement director.